NASDAQ:ELGXEndologix Stock Price, Forecast & News

Endologix's stock was trading at $0.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ELGX stock has decreased by 5.6% and is now trading at $0.8873. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Endologix.

Endologix is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Endologix.

Endologix, Inc. (NASDAQ:ELGX) posted its quarterly earnings data on Monday, May, 11th. The medical instruments supplier reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.13. The medical instruments supplier had revenue of $28.51 million for the quarter, compared to analyst estimates of $28.50 million. Endologix had a negative return on equity of 63.96% and a negative net margin of 44.65%. View Endologix's earnings history.

Endologix shares reverse split on the morning of Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.

Endologix issued an update on its first quarter 2020 Pre-Market earnings guidance on Monday, April, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $28.5-28.5 million, compared to the consensus revenue estimate of $30.73 million.

3 brokers have issued twelve-month target prices for Endologix's stock. Their forecasts range from $1.00 to $7.00. On average, they anticipate Endologix's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 350.8% from the stock's current price. View analysts' price targets for Endologix.

Media headlines about ELGX stock have trended somewhat positive on Friday, according to InfoTrie. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Endologix earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutEndologix.

Endologix saw a increase in short interest in May. As of May 15th, there was short interest totaling 490,900 shares, an increase of 30.2% from the April 30th total of 377,000 shares. Based on an average trading volume of 359,500 shares, the short-interest ratio is presently 1.4 days. Currently, 3.0% of the shares of the company are sold short. View Endologix's Current Options Chain.

Some companies that are related to Endologix include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR), Meridian Bioscience (VIVO) and Anika Therapeutics (ANIK). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Endologix investors own include CA (CA), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Och-Ziff Capital Management Group (OZM), Gran Tierra Energy (GTE), Belden (BDC) and Precision Drilling (PD).

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

Endologix's stock is owned by many different institutional and retail investors. Top institutional investors include Deutsche Bank AG (2.63%), NEA Management Company LLC (1.30%), Invesco Ltd. (0.78%), Parametric Portfolio Associates LLC (0.38%), King Wealth (0.34%) and Wedbush Securities Inc. (0.20%). Company insiders that own Endologix stock include Gregory D Waller, John Onopchenko, Thomas F Zenty III, Thomas Wilder and Vaseem Mahboob. View institutional ownership trends for Endologix.

ELGX stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, and Parametric Portfolio Associates LLC. View insider buying and selling activity for Endologix.

ELGX stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Invesco Ltd., King Wealth, and Wedbush Securities Inc.. Company insiders that have bought Endologix stock in the last two years include John Onopchenko, Thomas F Zenty III, and Vaseem Mahboob. View insider buying and selling activity for Endologix.

Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ELGX stock can currently be purchased for approximately $0.89.

Endologix has a market capitalization of $17.01 million and generates $143.37 million in revenue each year. The medical instruments supplier earns $-64,760,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Endologix employs 528 workers across the globe.

The official website for Endologix is www.endologix.com.

Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]